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Unstructured abstract 
A 66-year-old man presented with biochemical recurrence of prostate cancer 
and underwent fluciclovine (18F) PET/CT to detect sites of recurrence. He had 
a history of resected truncal stage IIIC malignant melanoma, with bilateral 
axillary node involvement on sentinel node biopsy, in complete remission for 3 
years.  
 
Fluciclovine (18F) PET/CT demonstrated an incidental fluciclovine-avid right 
axillary node (SUVmax=4.3). Diagnostic sampling confirmed recurrent 
malignant melanoma. 
 
Figure legend 
A 66-year-old man with a history of radical prostatectomy for prostate cancer, 
presented with biochemical recurrence (prostate specific antigen level 0.32 
ng/ml) and underwent fluciclovine (18F) PET/CT to detect sites of disease 
recurrence. He also had a history of resection of a truncal stage IIIC 4-mm 
non-ulcerated malignant melanoma, with bilateral axillary node involvement 
on sentinel node biopsy, in complete remission for 3 years. While the site of 
prostate cancer recurrence was not demonstrated, an incidental fluciclovine-
avid (SUVmax=4.3) 12-mm right axillary node was detected. Diagnostic 
sampling and subsequent right axillary node dissection two months later 
confirmed recurrent malignant melanoma. 
 
Fluciclovine (18F) / anti-1-amino-3-[18F]-fluorocyclobutane-1-carboxylic acid 
(FACBC) is a synthetic amino acid, recently FDA-approved for imaging 
recurrent prostate cancer1. It is predominantly transported into cells by high-
affinity glutamine transporter ASCT2, and leucine transporter LAT12, 3. There 
has been therapeutic interest in targeting glutamine metabolism by utilising 
ASCT2 inhibitors in melanoma4 as well as prostate cancer5, which in the case 
of melanoma, is fuelled by observation of a metabolic switch to glutamine 
dependence on developing resistance to BRAF inhibition6, 7. Disease 
detection aside, this raises potential application in patient selection and 
response assessment to such emerging therapies.  
 
Unlike fluorodeoxyglucose, which demonstrates non-specific uptake upon 
activation of both innate and adaptive immune response components, 
preclinical studies report uptake of fluciclovine only upon T- and B-cell 
activation, but not in granulocytes and macrophages8. Fluciclovine may 
therefore have the potential ability to selectively image T-cell modulation in 
the tumour microenvironment.  
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